SPOTLIGHT -
Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.
Bispecific Antibodies Promise to be ‘Transformative’ in Multiple Myeloma
A panel of experts reviews how the recent approval of teclistamab, a bispecific antibody, has changed the treatment landscape for patients with multiple myeloma.
Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
Ide-cel and kidney disease: the re(n)al-world experience with BCMA CAR-T
Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.
Oncology Peer Review On-The-Go: Treatment Considerations for Transplant-Ineligible Multiple Myeloma
CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.
FDA Grants Fast Track and RMAT Designations to CAR T Product for R/R Myeloma
The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.
Updated Data from KarMMA-3 Show Improved PFS in Relapsed/Refractory Myeloma
Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.